Diabetes Mellitus, Type 2 Clinical Trial
— DAPASALTOfficial title:
DAPASALT: An Open Label, Phase IV, Mechanistic, Three-Arm Study to Evaluate the Natriuretic Effect of 2-Week Dapagliflozin Treatment in Type 2 Diabetes Mellitus Patients With Either Preserved or Impaired Renal Function and Non-Diabetics With Impaired Renal Function
Verified date | May 2021 |
Source | AstraZeneca |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to evaluate how dapagliflozin mechanism of action is impacted by Type 2 Diabetes Mellitus status and kidney function
Status | Terminated |
Enrollment | 24 |
Est. completion date | March 20, 2020 |
Est. primary completion date | March 20, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: - Provision of signed and dated, written informed consent prior to any study specific procedures - Female and/or male aged between 18 years and =80 years - In the diabetic arms - a diagnosis of T2DM with HbA1c =6.5% (=48 mmol/mol) and <10% (<86 mmol/mol); and eGFR (CKD-EPI) between =25 and =50 mL/min/1.73m2 or between >90 and =130 mL/min/1.73m2 for patients aged 59 years or younger, between >85 and =130 mL/min/1.73m2 for patients aged 60 to 69 years, and between >75 and =130 mL/min/1.73m2 for patients aged 70 years or older at the Screening Visit (Visit 1) - In the non-diabetic arm, HbA1c <6.5% (<48 mmol/mol) and an eGFR (CKD-EPI) between =25 and =50 mL/min/1.73m2 at the Screening Visit (Visit 1) - Patient specific optimal antihypertensive dose of an angiotensin receptor blocker at least 6 weeks before study treatment - In the diabetic arm (Group 2) an appropriate stable dose of metformin, or sulphonylurea, or metformin+sulphonylurea as anti-diabetic therapy for the last 12 weeks before study treatment - Stable urinary sodium excretion on 2 successive 24-hr urinary sodium excretion measurements. - In the diabetic arm with impaired renal function (Group 1), a stable insulin dosing (intermediate, long-acting, premixed insulin, basal bolus insulin) for the last 12 weeks prior to Visit 4 (Day 1), as judged by the Investigator. Metformin or sulphonylurea, or metformin+sulphonylurea together with insulin would be accepted, but is not mandatory. If used, stable dose of metformin or sulphonylurea, or metformin+sulphonylurea as anti-diabetic therapy for the last 12 weeks prior to Visit 4 (Day 1) is required. Exclusion Criteria: - Diagnosis of Type 1 Diabetes Mellitus - Any of the following cardiovascular/vascular diseases within 3 months prior to signing the consent; myocardial infarction, cardiac surgery or revascularization, unstable angina, unstable heart failure, heart failure NYHA Class IV, transient ischemic attack or significant cerebrovascular disease, unstable or previously undiagnosed arrhythmia - Symptoms/complaints suggestive of established neurogenic bladder and/or incomplete bladder emptying - History of bladder cancer, diagnosis of polycystic kidney disease, history or current lupus nephritis or unstable or rapidly progressing renal disease - UACR >1000 mg/g at screening - Current/chronic use of the following medications: any anti-diabetic medication with the exception of metformin, sulphonylurea, angiotensin converting enzyme inhibitors, insulin (insulin only allowed in Group 1), oral glucocorticoids, non-steroidal anti-inflammatory drugs, immune suppressants, chemotherapeutics, antipsychotics, tricyclic antidepressants and monoamine oxidase inhibitors - Receiving immunosuppressive or other immunotherapy for primary or secondary renal disease within 6 months prior to screening - Current treatment or treatment within the last 2 weeks prior to screening with diuretics including loop diuretics, thiazides, and mineralocorticoid antagonists |
Country | Name | City | State |
---|---|---|---|
Netherlands | Research Site | Almelo | |
Netherlands | Research Site | Amsterdam | |
Sweden | Research Site | Örebro | |
Sweden | Research Site | Stockholm |
Lead Sponsor | Collaborator |
---|---|
AstraZeneca |
Netherlands, Sweden,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in 24-hour Sodium Excretion From Baseline to Start of Treatment | Change in 24-hour sodium excretion during dapagliflozin treatment between baseline and average of Days 2 to 4 within each study group in patients with T2DM with preserved kidney function and in non-diabetics with impaired kidney function was assessed. | From baseline (Day -3 to Day -1) to start of treatment (Day 2 to Day 4) | |
Secondary | Change in 24-hour Sodium Excretion From Baseline to End of Treatment and From End of Treatment to Follow-up | Average change in 24-hour sodium excretion from average baseline values to average end of treatment values (Day 12 to 14); and from average end of treatment values (Day 12 to 14) to average values during follow-up (Day 15 to 17). | From baseline (Day -3 to Day -1) to end of treatment (Day 12 to 14); and from end of treatment (Day 12 to 14) to follow-up (Day 15 to 17) | |
Secondary | Change in 24-hour Glucose Excretion From Baseline to Start of Treatment | Average change in 24-hour glucose excretion from average baseline values to average start of treatment values (Day 2 to 4). | From baseline (Day -3 to Day -1) to start of treatment (Day 2 to 4) | |
Secondary | Change in 24-hour Glucose Excretion From Baseline to End of Treatment | Average change in 24-hour glucose excretion from average baseline values to average end of treatment values (Day 12 to 14) | From baseline (Day -3 to Day -1) to end of treatment (Day 12 to 14) | |
Secondary | Change in 24-hour Glucose Excretion From End of Treatment to Follow-up | Average change in 24-hour glucose excretion from average end of treatment values (Day 12 to 14) to average values during follow-up (Day 15 to 17). | From end of treatment (Day 12 to 14) to follow-up (Day 15 to 17) | |
Secondary | Change in Mean 24-hour Systolic Blood Pressure From Baseline to Start of Treatment | Change in mean 24-hour systolic blood pressure from baseline to start of treatment (Day 4) | From baseline (Day -1) to start of treatment (Day 4) | |
Secondary | Change in Mean 24-hour Systolic Blood Pressure From Baseline to End of Treatment | Change in mean 24-hour systolic blood pressure from baseline to end of treatment (Day 13). | From baseline (Day -1) to end of treatment (Day 13) | |
Secondary | Change in Mean 24-hour Systolic Blood Pressure From End of Treatment to End of Follow-up | Change in mean 24-hour systolic blood pressure from end of treatment (Day 13) to end of follow-up (Day 18). | From end of treatment (Day 13) to end of follow-up (Day 18) | |
Secondary | Change in Plasma Volume From Baseline to Start of Treatment | Change in plasma volume from baseline to start of treatment (Day 4). | From baseline (Day 1) to start of treatment (Day 4) | |
Secondary | Change in Plasma Volume From Baseline to End of Treatment | Change in plasma volume from baseline to end of treatment (Day 14). | From baseline (Day 1) to end of treatment (Day 14) | |
Secondary | Change in Plasma Volume From End of Treatment to End of Follow-up | Change in plasma volume from end of treatment (Day 14) to end of follow-up (Day 18). | From end of treatment (Day 14) to end of follow-up (Day 18) | |
Secondary | Change in Extracellular Volume From Baseline to Start of Treatment | Change in extracellular volume from baseline to start of treatment (Day 4). | From baseline (Day 1) to start of treatment (Day 4) | |
Secondary | Change in Extracellular Volume From Baseline to End of Treatment | Change in extracellular volume from baseline to end of treatment (Day 14). | From baseline (Day 1) to end of treatment (Day 14) | |
Secondary | Change in Extracellular Volume From End of Treatment to End of Follow-up | Change in extracellular volume from end of treatment (Day 14) to end of follow-up (Day 18). | From end of treatment (Day 14) to end of follow-up (Day 18) | |
Secondary | Change in 24-hour Urine Albumin:Creatinine Ratio (UACR) | Average change in mean 24-hour urine albumin:creatinine ratio (UACR) from average baseline to Day 4; and from average baseline values to average end of treatment values (Day 12 to 14). | From baseline (Day -3 to Day -1) to start of treatment (Day 4); and from baseline (Day -3 to Day-1) to end of treatment (Day 12 to 14) | |
Secondary | Pharmacokinetics of Dapagliflozin on Day 4 and Day 14 | Dapagliflozin plasma concentration on Day 4 (pre-dose) and Day 14 (pre-dose, 1h, 2h, 4h post-dose) | At pre-dose (Day 4) and at pre-dose, 1h, 2h, 4h post-dose (Day 14) | |
Secondary | Number of Patients With AEs and SAEs | An AE is the development of an undesirable medical condition or the deterioration of a pre-existing medical condition following or during exposure to a pharmaceutical product, whether or not considered causally related to the product. SAE is an AE that results in any untoward medical occurrence that results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability, or is a significant medical event. | From Day 1 until Day 18 (Follow-up) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05666479 -
CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery
|
||
Completed |
NCT05647083 -
The Effect of Massage on Diabetic Parameters
|
N/A | |
Active, not recruiting |
NCT05661799 -
Persistence of Physical Activity in People With Type 2 Diabetes Over Time.
|
N/A | |
Completed |
NCT03686722 -
Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin
|
Phase 1 | |
Completed |
NCT02836704 -
Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose)
|
Phase 4 | |
Completed |
NCT01819129 -
Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes
|
Phase 3 | |
Completed |
NCT04562714 -
Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy
|
N/A | |
Completed |
NCT02009488 -
Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)
|
Phase 1 | |
Completed |
NCT05896319 -
Hyaluronic Acid Treatment of the Post-extraction Tooth Socket Healing in Subjects With Diabetes Mellitus Type 2
|
N/A | |
Recruiting |
NCT05598203 -
Effect of Nutrition Education Groups in the Treatment of Patients With Type 2 Diabetes
|
N/A | |
Completed |
NCT05046873 -
A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People
|
Phase 1 | |
Terminated |
NCT04090242 -
Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes
|
N/A | |
Completed |
NCT04030091 -
Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus
|
Phase 4 | |
Completed |
NCT03620357 -
Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D)
|
N/A | |
Completed |
NCT03604224 -
A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
|
||
Completed |
NCT01696266 -
An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
|
||
Completed |
NCT03620890 -
Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy
|
Phase 4 | |
Withdrawn |
NCT05473286 -
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice
|
||
Not yet recruiting |
NCT05029804 -
Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes
|
N/A | |
Completed |
NCT04531631 -
Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes
|
Phase 2 |